USFDA conducts inspection at Zydus Lifesciences Ahmedabad manufacturing facility

USFDA conducts inspection at Zydus Lifesciences Ahmedabad manufacturing facility

The inspection was a pre-approval inspection (PAI) and a GMP Audit that concluded with three observations.

FPJ Web DeskUpdated: Sunday, March 26, 2023, 10:34 AM IST
article-image
USFDA conducts inspection at Zydus Lifesciences Ahmedabad manufacturing facility | Image: Zydus (Representative)

USFDA conducted an inspection at Zydus Lifesciences Limited's manufacturing facility SEZ-1 at Pharmez, Ahmedabad from March 20 to March 24, 2023, the company announced through an exchange filing. The inspection was a pre-approval inspection (PAI) and a GMP Audit that concluded with three observations.

The company said that there were no data integrity related observations and the company is addressing these observations.

Zydus received final approval from USFDA for Lubiprostone Capsules, the company announced on March 24.

Zydus Lifesciences shares

The shares of Zydus Lifesciences on Friday closed at Rs 480.05, down by 0.47 per cent.

(To receive our E-paper on WhatsApp daily, please click here.  To receive it on Telegram, please click here. We permit sharing of the paper's PDF on WhatsApp and other social media platforms.)

RECENT STORIES

Government to divest 3% stake in state-owned Coal India

Government to divest 3% stake in state-owned Coal India

India's GDP beats estimates with 6.1% growth in Jan-March quarter of FY23

India's GDP beats estimates with 6.1% growth in Jan-March quarter of FY23

India's 8 core sectors register higher production; read on to know why they matter

India's 8 core sectors register higher production; read on to know why they matter

Everest industries rewards employees with 6859 equity shares under ESOP

Everest industries rewards employees with 6859 equity shares under ESOP

Key takeaways from RBI's report on the surge of digital payment fraud in FY23

Key takeaways from RBI's report on the surge of digital payment fraud in FY23